Prognose

Analytikernes gennemsnitlige kursmål er 85,04 € (+50,65 %). Medianen er 93,61 € (+65,83 %).

Køb	6
Behold	0
Sælg	1

Nyheder Til nyhedsfeedet

Liquidia reports strong YUTREPIA growth, pipeline expansion and positive profitability

Liquidia said at the Wells Fargo Healthcare Conference that YUTREPIA generated $170 million in revenue in Q2 2026 and that quarterly sales have increased by about $40 million in each of the past three quarters. About 75% of prescriptions are for treatment‑naive patients, and the company reported EBITDA of roughly $100 million, net income of about $80 million and an additional $60 million of cash flow in the quarter. Liquidia is expanding its commercial and clinical programs with 8–10 planned studies in the next 12 months, plans L606 as a follow‑on program, expects long‑term revenue above $1 billion, but faces an outstanding patent ruling. » Mere på de.investing.com
Liquidia Corporation: Yutrepia launch outpaces expectations, litigation likely to be resolved

The Summers Value Fund named Liquidia Corporation a top contributor after the Yutrepia launch continued to exceed investor expectations and is expected to sustain momentum. The fund expects a near-term favorable resolution of litigation that could unlock further gains. Liquidia shares are up 141.61% over the past year (down 22.08% in the past month) and the company has a market capitalization of $6.24 billion. » Mere på finance.yahoo.com
Greenhaven Road Capital posts Q2 gain, trims concentration and realized short-term gain on Liquidia

Greenhaven Road Capital reported an approximate 11% net return in Q2 2026 and said it will lower portfolio concentration, increase positions with near-term catalysts and take a more proactive approach to profit-taking. The firm emphasized continued focus on high-quality businesses and research that challenges consensus as several large holdings face near-term events. Greenhaven noted it sold a portion of its Liquidia position after a >30% pre-verdict rise, realizing a short-term gain, and will reassess the investment following the patent dispute outcome. » Mere på finance.yahoo.com

Virksomhedstal

I det seneste kvartal havde Liquidia en omsætning på 150,43 mio. € og et nettoresultat på 65,47 mio. €

(EUR)	juni 2026	YoY
Omsætning	150,43 mio.	1.906,36 %
Bruttofortjeneste	140,31 mio.	2.091,83 %
Nettoresultat	65,47 mio.	285,60 %
EBITDA	77,45 mio.	356,14 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	5,14 mia. €
Antal aktier	88,93 mio.
Højeste/laveste i 52 uger	81,14 € - 18,33 €
Udbytte	Nej
Beta	0,54
P/E (PE Ratio)	42,53
PEG (PEG Ratio)	0,02
K/I (PB Ratio)	30,40
P/S (PS Ratio)	13,16

Virksomhedsprofil

Liquidia Corporation, ein biopharmazeutisches Unternehmen, entwickelt, produziert und vermarktet verschiedene Produkte für ungedeckte Patientenbedürfnisse in den Vereinigten Staaten. Zu seinen Produktkandidaten gehört YUTREPIA, eine inhalative Trockenpulverformulierung von Treprostinil für die Behandlung der pulmonalen arteriellen Hypertonie. Das Unternehmen vertreibt auch generische Treprostinil-Injektionen in den Vereinigten Staaten. Die Liquidia Corporation wurde 2004 gegründet und hat ihren Hauptsitz in Morrisville, North Carolina.